Enfusion

Enfusion, Inc. engages in the development of cloud-native multi-tenant software for alternative and institutional investment managers. It is a software-as-a-service firm that develops a platform to eliminate technology and information barriers, and simplify investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset. The company was founded by Tarek Hammoud, Stephen M. Malherbe, Oleg Movchan, and Scott Werner in 2006 and is headquartered in Chicago, IL.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Enfusion reports robust Q4 earnings, eyes growth in new markets

Enfusion's Q4 2022 performance reflects financial strength and growth momentum, supported by revenue growth, client wins, and strategic guidance for 2023.
The company's strengths lie in its market positioning, regional focus, and commitment to innovation, while challenges include managing churn levels and scaling managed services profitably.
Opportunities in expanding into new markets, enhancing client relationships, and driving revenue growth through strategic initiatives position Enfusion for continued success and market leadership.
Overall, Enfusion's proactive approach to market dynamics, client services, and product development sets a solid foundation for sustained growth and value creation, aligning with investor expectations and industry trends.

Enfusion reports robust Q1 earnings, eyes growth amid market challenges

Enfusion's Q1 2023 Earnings Call highlighted strong financial performance, strategic partnerships, and a positive outlook for the year. Despite market challenges, the company remains resilient and focused on growth opportunities. Management's reaffirmation of guidance and optimism for the future reflect confidence in Enfusion's trajectory.

Enfusion reports strong Q2 earnings, eyes growth through strategic partnerships

Enfusion's Q2 performance showcased growth and profitability despite challenges. The company's strategic focus on efficiency, partnerships, and tailored pricing strategies bodes well for future expansion and revenue generation.

Enfusion reports robust Q3 performance and eyes sustainable 20% growth

Enfusion's Q3 performance showcased strong revenue growth, client additions, and global market expansion, with a focus on Portfolio WorkBench.
Confidence in reaffirmed guidance, positive organic growth trends, and strategic investments position Enfusion for sustained success.
Challenges include managing quarterly fluctuations, balancing investments for growth, and addressing strategic clarity in key areas.
Opportunities lie in leveraging product capabilities, targeted investments, ACV growth, and global market expansion for continued success.

Enfusion reports robust Q4 earnings, eyes growth through technology innovation

Enfusion's strong Q4 performance, focus on SaaS platform benefits, and strategic guidance for 2024 demonstrate a commitment to growth and innovation. The company's emphasis on client service, technology enhancements, and market opportunities positions them well for future success. Enfusion's Investor Day in Fort Lauderdale on March 19 will showcase their integrated investment technology platform and growth outlook.

Enfusion excels in Q1 performance, eyes growth through client focus

Enfusion's Q1 2024 performance showcased strong revenue growth, client wins, and margin expansion, driven by efficient client onboarding and product enhancements.
The company's strengths in client relationships, differentiated offerings, and strategic pricing position it well for future growth and value creation.
Challenges in client fee pressure, resource allocation, and evolving seasonality require strategic solutions, while opportunities in product enhancements and growth algorithm offer avenues for expansion.
Enfusion's commitment to delivering on promises, shareholder value creation, and differentiation underpin its optimistic outlook and focus on long-term success.

Enfusion reports robust Q2 earnings, eyes global expansion opportunities

Enfusion's Q2 performance reflects strong revenue growth, client acquisitions, and product innovation.
The company's resilience to market forces and global expansion efforts position it for continued success.
Challenges lie in maintaining growth momentum, deepening client relationships, and adapting to market dynamics.

Enfusion reports robust Q3 growth, eyes sustained expansion and innovation

Enfusion's Q3 2024 earnings call highlighted strong financial performance, client acquisitions, and product advancements. The company's tightened revenue and EBITDA guidance for 2024 reflects management's confidence in continued growth. Analyst inquiries centered on strategic alternatives, product innovations, and revenue drivers, indicating investor interest in Enfusion's future prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of cloud-based investment management software and services, today announced two internal executive promotions. Iris Xinwei Wang will serve as Enfusion's Chief Strategy Officer, based in New York. Additionally, Lotte Tønsberg will serve as the London-based Head of Sales for EMEA. “We are thrilled to announce the promotion of Iris and Lotte, both of whom have been instrumental in our globa

Enfusion Elevates Iris Xinwei Wang to Chief Strategy Officer and Lotte Tønsberg to Head of EMEA Sales and Executive Director, EMEA

CHICAGO--(BUSINESS WIRE)--Built In today named Enfusion ("Enfusion") (NYSE: ENFN), a leading provider of cloud-based investment management software and services, as one of the best companies to work for in Chicago as part of the Built In Best Places To Work Awards, in the Best Large Companies to Work For category. The annual awards program includes companies of all sizes, from startups to those in the enterprise, and honors both remote-first employers as well as companies in the eight largest t

Built In Honors Enfusion in Its Esteemed 2022 Best Places to Work Awards

NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of cloud-based investment management software and services, and Coinbase Global Inc., through Coinbase Prime, today announced that the two firms will establish connectivity between their respective systems to enable financial institutions and investment managers to seamlessly trade cryptocurrency at Coinbase. This announcement marks Coinbase's first connectivity with an order execution m

Enfusion and Coinbase to Bring Seamless Digital Asset Connectivity to Institutions

NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of cloud-based investment management software and services serving 680+ investment managers, today announced significant mobile innovations for its market-leading front-to-back-office investment management platform, enabling real-time access to a broader array of information for Enfusion clients across desktop, web, and mobile. More robust order and execution management (OEMS) functional

Enfusion Changes the Game for Portfolio Managers and Traders with Full Portfolio Transparency and Control on Mobile

NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of cloud based investment management software and services, recently announced the opening of a new office in Sydney, Australia, which will be Enfusion's first in Oceania. The location in Sydney will allow Enfusion to adequately respond to the increased demand for innovative operational solutions and extend its best-in-class SaaS platform and technology-enabled services to a growing base

Enfusion Expands Global Footprint with New Office in Sydney, Australia

NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of cloud based investment management software and services, today announced the appointment of experienced human capital management professional, Bronwen Bastone, as Chief People Officer, and global financial industry veterans Jan Hauser and Kathleen DeRose to its Board of Directors. “We are pleased to welcome Bronwen, Jan, and Kathleen, all of whom bring significant industry experience

Enfusion Welcomes New Chief People Officer, Expands Board of Directors

NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Enfusion, Inc. ("Enfusion"), a leading provider of cloud-based investment management software and services, today announced financial results for the third quarter ended September 30, 2021. “We had an excellent third quarter and are thrilled with our business results. Our cloud-native SaaS solution continues to deliver the tools investment managers need to better manage their business and operational barriers so they can focus on what they do best

Enfusion Announces Third Quarter 2021 Results

NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Enfusion, Inc. ("Enfusion"), a leading provider of cloud based investment management software and services, today announced that it will report its third quarter fiscal year 2021 financial results after the U.S. financial markets close on Thursday, December 2, 2021. Webcast and Conference Call Details In conjunction with this announcement, Enfusion will host a conference call at 2:00 PM (PT) / 5:00 PM (ET) on Thursday, December 2, 2021 during whic

Enfusion Announces Third Quarter 2021 Earnings Release Date

Sunlight Financial Holdings

DUBLIN, Calif.--(BUSINESS WIRE)-- #unicorn--Vagaro announced it has raised funding valuing the company at $1 billion.

Vagaro Achieves $1 Billion Valuation with New Investment from FTV Capital

Enfusion modernizes investment management. The company has seen solid traction, and investors have priced in this momentum quite aggressively, too aggressively to my taste.

Enfusion: Modernizing Investment, Yet I Am Not Investing

NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Enfusion, Inc. ("Enfusion"), a leading provider of cloud-based investment management software and services, today announced the closing of its initial public offering of 21,562,500 shares of Class A common stock, including the exercise in full of the underwriters' option to purchase up to an additional 2,812,500 shares, at a price of $17.00 per share. The offering comprised the sale of 16,839,107 shares of Class A common stock offered by Enfusion

Enfusion Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Enfusion Inc. ENFN, +20.15% was well received on its Wall Street debut, as the Chicago-based investment management software company's stock opened 17.6% above its IPO price. The company raised $260.5 million as it sold 15.32 Class A million shares in its initial public offering, which the company said overnight priced at $17 a share, at the top of the expected range of between $15 and $17 a share.

Enfusion stock opens 18% above IPO price to value investment management software company at $2.3 billion

Enfusion Inc. ENFN, is set for its public debut Thursday, as the Chicago-based investment management software company's initial public offering priced overnight at $17 a share, at the top of the expected range of between $15 and $17 a share. The company sold 15.32 million Class A shares in the IPO to raise $260.5 million and selling shareholders sold 3.43 million shares to raise $58.3 million.

Enfusion valued at $1.9 billion as IPO priced at top of expected range

NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Enfusion, Inc. ("Enfusion"), a leading provider of cloud-based investment management software and services, today announced the pricing of its initial public offering of 15,322,660 shares of its Class A common stock offered by Enfusion and 3,427,340 shares of Class A common stock to be sold by certain of Enfusion's existing stockholders at a price to the public of $17.00 per share. In addition, the underwriters have been granted a 30-day option to

News for Enfusion Stock (ENFN)